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Abstract
Background: Angiotensin II type-1 receptor antibody (AT1RAb) has been reported
to cause antibody mediated rejection (AMR) in kidney transplant recipients possibly
by contraction of renal arteries. We here report 2 kidney transplant recipients with
elevated AT1RAbs and negative HLA donor specific antibodies (DSA) and anti-
major histocompatibility complex class I chain-related gene A (MICA) Abs who
received therapeutic plasma exchange (TPE) treatment followed by IVIG.
Case 1: Thirty-eight-year-old patient received second kidney transplant for end stage
renal disease (ESRD) with chronic rejection. Three years post-transplant, she devel-
oped AMR with AT1RAb level >40 U/mL. She received 5 TPE and AT1RAb
decreased by 20%, and biopsy showed improvement of AMR. She received another
3 TPE and AT1RAb decreased by 60%. Her creatinine (Cr) was stabilized at around
1.4 mg/dL.
Case 2: Twenty-four-year-old patient received kidney transplant for ESRD with
unclear etiology. Two weeks post-transplant, her Cr rose with AT1RAb level at
18 U/mL and biopsy showed possible AMR. She received 6 TPE treatments and
AT1RAb decreased by 55% and biopsy showed improvement of AMR. She received
weekly TPE for subsequently rising AT1RAb but TPE was discontinued because of
unsuccessful decrease of AT1RAb. Her Cr was stabilized at around 1.7 mL/dL.
Conclusion: We reported 2 patients who received TPE treatments to decrease
AT1RAbs. A course of TPE treatment successfully decreased AT1RAb. Histologi-
cal improvement was observed quickly and Cr was also stabilized following the
TPE treatment. Further study is necessary to determine the optimal use of TPE in
renal transplant recipients with AT1RAbs.
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1 | INTRODUCTION
Some renal transplant recipients develop antibody mediated
rejection (AMR) without detectable HLA donor specific anti-
bodies (DSA) in sera. In recent years, angiotensin II type-1
receptor antibody (AT1RAb) has been reported to be associ-
ated with kidney AMR, especially refractory AMR, possibly
by contraction of renal arteries. Therapeutic plasma exchange
(TPE) has been increasingly applied to reduce HLA DSA in
kidney AMR; less is known regarding the role of TPE in
AMR because of non-HLA Abs such as AT1RAb. Although
there are several published reports describing the use of TPEInstitution at which the work was performed: University of Michigan.
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in the treatment of AT1RAb associated AMR, the efficacy of
TPE in reducing AT1RAb levels has not been reported.
Our institution has been implementing AT1RAb testing
for the kidney transplant recipients with biopsy proven or
suspicious for AMR on renal biopsy without HLA DSA, and
a course of treatment with 5–6 TPE followed by IVIG has
been applied on those patients as same as on patients with
HLA DSA. We investigated AT1RAb and creatinine
(Cr) levels before and after TPE treatments in those patients
and report 2 patients here.
2 | MATERIALS AND METHODS
2.1 | Patients
Renal transplant recipients with elevated AT1RAbs, nega-
tive HLA DSA and negative antimajor histocompatibility
complex class I chain-related gene A (MICA) Abs who
received TPE treatments for histologically proven or suspi-
cious for AMR between January 2014 and December 2016
were identified in our institutional renal transplant database.
Among those patients, a total of 9 patients with elevated
AT1RAb levels before TPE treatment were identified.
Among them, 2 patients had positive HLA DSA, 3 patients
lack follow-up laboratory tests, and 2 patients had follow-up
AT1RAb tests more than 3 months after the last TPE proce-
dure. The remaining 2 patients’ demographics, causes of kid-
ney failure, types of donor, graft age at the first TPE
procedure, and angiotensin II receptor blockers (ARB) use
are shown in Table 1. Of note, no patient received rituximab
at the time of TPE treatment.
2.2 | Angiotensin II type-1 receptor antibody
Serum AT1RAb level was measured using enzyme-linked
immunosorbent assay (ELISA) test (One Lambda, Canoga
Park, CA) and reported as high (>17 U/mL), intermediate
(12–17 U/mL), and negative (<12 U/mL). Because of the
lack of protocol to test AT1RAb level, AT1RAb levels were
tested in various time points after TPE treatment. No patient
was tested for AT1RAb prior to their transplantations and
this test is currently unavailable for validation process at our
institution.
2.3 | Therapeutic apheresis
In our facility, renal transplant recipients with high DSA
against HLAs or non-HLA Abs and/or biopsy proven AMR
receive a course of TPE treatment (5–6 TPE followed by
IVIG infusion each time). Additional TPE may be performed
after the initial course based on the patient’s response to the
treatment or post-TPE antibody level (eg, AT1RAb, HLA
DSA). TPE procedures were performed using either Cobe
Spectra or Spectra Optia Apheresis System (TerumoBCT,
Lakewood, CO), and one plasma volume was exchanged per
procedure. Citrate dextrose solution A was used as an antico-
agulant and 5% albumin was used as a replacement fluid.
3 | RESULTS
3.1 | Case 1
Patient A was a 42-year-old female with focal segmental
glomerulosclerosis who received her first living related
donor kidney transplant at age 22, and a second deceased
donor transplant because of a chronic rejection of the trans-
planted kidney at age 38. Three years post-transplant, her Cr
started to rise from 0.7 to 1.35 mg/dL and a biopsy showed
Banff grade 2 AMR1,2, grade 2A T-cell mediated rejection
(TCMR), and grade 3 interstitial fibrosis and tubular atrophy
(IFTA) (Table 2). Serum HLA DSA and antiMICA Abs
were negative, but high level AT1RAb was identified at
>40 U/mL (Figure 1, A). She received 5 TPEs each fol-
lowed by IVIG every other day over 9 days and started ARB
treatment. The AT1RAb level measured 2 days after a
course of TPE treatment decreased to 32 U/mL (20.0%
reduction), and histology showed grade 0 AMR and 1B
TCMR 26 days after the last TPE treatment. Over the course
of the next month, her Cr slowly increased to 1.64 mg/dL,
accompanied by a rise in AT1RAb (>40 U/mL). She was
treated with 3 more TPE treatments every other day and her
AT1RAb level decreased to 16 U/mL (60.0% reduction).
Although AT1RAb level increased slightly to 20 U/mL, kid-
ney biopsy still showed grade 0 AMR 3 months after the last
TPE. Her Cr at approximately 1 year after the last TPE was
at around 1.4 mg/dL, and her most recent Cr in January
2018 was 1.31 mg/dL. HLA DSA has been negative to date.
TABLE 1 Demographics and angiotensin II antagonist use
Patient Gender Race
Cause of kidney
failure
Type of
donor
Age at
transplant
Age at
first TPE
Graft age at first
TPE, days
ARB
use
A Female AA FSGS Living related 22 – – –
Chronic rejection Deceased 38 42 1098 Yes
B Female AA Unclear etiology Deceased 24 25 61 No
Abbreviation: AA, African American; ARB, angiotensin II receptor blocker; DM, diabetes mellitus; FSGS, focal segmental glomerulosclerosis; HTN, hypertension;
TPE, therapeutic plasma exchange.
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3.2 | Case 2
Patient B was a 25-year-old female with renal failure
because of unclear etiology who received a deceased donor
kidney transplant at age 24. Her Cr started to rise 2 weeks
post-transplant from 1.40 to 2.68 mg/dL (Figure 1,B) with-
out detectable HLA DSA and anti-MICA Abs. A biopsy
showed Banff grade 0 AMR, grade 0 TCMR and grade
1 IFTA (Table 2), but had focally severe endothelial
swelling and cell injury suggesting process for AMR. Her
AT1RAb level was found to be elevated at 18 U/mL. She
received 6 TPE each followed by IVIG every other day over
11 days and her AT1RAb level decreased to 8 U/mL (55.6%
reduction). Her Cr was improved to 1.98 mg/dL, and biopsy
also showed improved arteriopathy 24 days after a course of
TPE. However, she was started on weekly TPE treatment for
the next 5 weeks because of rising AT1RAb (12 U/mL)
TABLE 2 Kidney biopsy results
Patient
Renal
biopsy date
AMR
grade
TCMR
grade
IFTA
grade
Peritubular
capillary C4d Change regarding AMR
A July 10, 2015 2 2A 3 Focal, weak Severe tubulitis and capillaritis
August 14, 2015 0 1B 3 Negative Reduction in interstitial inflammation, improvement in the
capillaritis, persistent tubulitis
November
20, 2015
0 – 3 Negative No change compared to previous biopsy
B March 18, 2016 0 0 1 Negative Segmental glomerulitis and vasculopathy
April 28, 2016 0 0 2 Negative Increased interstitial fibrosis
July 5, 2016 0 0 1 Negative Focal glomerulopathy and interstitial fibrosis
Abbreviation: AMR, antibody mediated rejection; ICMR, T-cell mediated rejection; IFTA, interstitial fibrosis and tubular atrophy; TPE, therapeutic plasma exchange.
FIGURE 1 AT1RAb level, creatinine level and the timing of TPE and kidney biopsies. Abbreviation: AT1RAb: angiotensin II type-1 antibody; Cr,
creatinine; TPE, therapeutic plasma exchange
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2 weeks after completing TPE. Her AT1RAb levels mea-
sured before her fifth weekly TPE treatment showed increase
to 16 U/mL, therefore, TPE was discontinued. Kidney
biopsy 25 days after the last TPE still showed grade 0 AMR.
Clinically, her Cr remained stable at around 1.7 mL/dL for
10 months after the last TPE. She had subsequent CMV
infection, which caused mild deterioration of kidney func-
tion and her most recent Cr in March 2018 was 2.75 mg/dL.
HLA DSA has been negative to date.
4 | DISCUSSION
The majority of AMR in renal transplantation is attributed to
DSA to HLA antigens. In recent years, however, several non-
HLA Abs have been linked to AMR including anti-endothe-
lial cell Abs, MICA Abs, antiAT1RAbs, anti-endothelin-1
type A receptor Abs, anti-poly-reactive Abs, anti-LG3 Abs
and anti-vimentin Abs.3,4
AT1R mediates physiological actions of angiotensin II
(ATII) in many organs including kidney. ATII promotes
vasoconstriction, inflammation, thrombosis, and vascular
remodeling,5 and AT1R regulates arterial blood pressure,
electrolyte and water balance, and renal function.6 Therefore,
hyperactivation of AT1R by AT1RAbs can cause hyperten-
sion and kidney dysfunction with vasoconstriction and
thrombosis. AT1RAb can be autoimmune or alloimmune
Ab. Preoperative positive AT1R using ELISA is found in
23%–47.2% of the patients who received first or multiple
kidney transplantations,7–10 de novo development of
AT1RAb after the transplantation is reported in 45% of the
pediatric patients,10 and 9.4% of the patients with rejection
are reported to have AT1RAbs.11 AT1RAb is also associated
with steroid refractory vascular rejection or higher rate of
late graft loss.7,8,10,12–14 Banasik et al.8 reported that patients
with AT1RAbs run a higher risk of graft failure indepen-
dently of classical immunological risk factors, but not acute
rejection or hypertension.
There are some reports in which TPE was used to treat
AMR in kidney transplant recipients with AT1RAbs. Jobert
et al. reported a case of AMR in a kidney transplant recipient
with AT1RAb, who received 6 TPE procedures with 1.5
plasma volume exchange.15 Fuss et al. used 3–11 TPE pro-
cedure to treat 6 kidney AMR patients with AT1RAbs.16
Lee et al.17 treated 11 cases of AT1RAb associated AMR
with a combination of TPE and IVIG, sometimes followed
by rituximab (9/12), antithymocyte globulin (5/12), or borte-
zomib (1/12). All patients experienced clinical improvement
and/or resolution of AMR. None of these reports, however,
measured AT1RAb level after TPE treatment or analyzed
role and efficacy of TPE in reducing AT1RAb, and correla-
tion with clinical outcomes. Our cases show that 1 course of
5–6 TPE treatment, followed by IVIG, successfully reduces
AT1RAb level by 20.0% and 55.6%, median 37.8%. This
rate is similar to the reduction rates of HLA DSA in kidney
transplant recipients with AMR that we previously reported
elsewhere.18 However, the effect of TPE was temporally and
AT1RAb rebound and increase over the time were also
observed, which indicates that follow-up of these patients is
critical. Some of the cases in these reports received a combi-
nation of treatment with TPE and ARB, however, report for
an effect of ARB only on renal AMR caused by AT1RAbs
was not found at this time. It may be because transplant
nephrologists have been reluctant to use ARB because of
possible decreases in organ perfusion and filtration men-
tioned by Dragun et al.13
The improvement of kidney function was also observed
after the TPE treatment. Cr was stabilized without further
increase. Therefore, it may be important to treat patients with
biopsy proven or suspicious for AMR without HLA DSA,
even if AT1RAb testing is not available, to prevent further
deterioration of kidney function, especially when those
patients were proven to have AT1RAbs which are thought to
have a higher probability for late graft failure as mentioned
above. In addition, there is a possibility that these patients
had other unknown antibodies against donor kidney in addi-
tion to AT1RAb that could be also decreased by TPE treat-
ment and medications, which might be taking some role in
improvement of biopsy or kidney function.
The current Banff histologic classification for kidney
AMR is based primarily on AMR resulting from HLA
DSA.1,2 Although the Banff classification is also used for
non-HLA AMR, the mechanisms underlying renal damage
and dysfunction may differ, which could impact biopsy
results. Specifically, HLA Abs frequently cause tissue dam-
age through complement cascade activation. As a result,
biopsy results in HLA DSA-mediated AMR often show C4d
positivity on peritubular capillaries. In contrast, kidney fail-
ure and AMR because of AT1RAb are thought to be caused
by renal artery vasoconstriction.19 The reason that a negative
C4d is a common finding in AT1RAb-mediated
AMR15,16,20,21 may be because complement may not be
involved for kidney dysfunction. In addition, vasculitis,
thrombosis, and glomerulopathy may be common and the
predominant histologic findings. Lim et al.22 did not find an
association between peritubular capillary C4d staining and
AT1RAb, however, reported several cases with positive C4d
staining. In our 2 patients, patient A had a weak C4d stain-
ing which disappeared after TPE treatment and patient B had
negative C4d staining on biopsies. Overall, the histological
abnormalities were improved after a course of TPE treatment
in both patients, which may suggest removing AT1RAbs by
TPE and suppression of Ab production by medications, may
be able to decrease vasoconstriction quickly and to provide
prevention of further damage on kidney.
In summary, we presented a first report on efficacy of
TPE treatment followed by IVIG in reducing AT1RAb level
in 2 patients. A course of TPE decreased AT1RAb by
median 37.8% measured within 1 month after the last TPE.
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However, rebound and subsequent increase of AT1RAb was
also observed, therefore, follow-up of AT1RAb level is
important when AT1RAb lab test is available. Histological
improvement in AMR was observed after a course of TPE
treatment and Cr did not show further deterioration of the
kidney function in several months, which may suggest
decreased level of AT1RAb by treatment with TPE followed
by IVIG may be able to decrease vasoconstriction caused by
AT1RAb and to prevent further deterioration of kidney func-
tion. A further study is needed to determine if TPE treatment
is more favorable over ARB treatment, and optimal use of
TPE in renal transplant patients with AT1RAbs.
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